MiMedx Q3 net sales beat estimates

MiMedx

29/10/2025 20:08

Overview

MiMedx Q3 net sales rise 35% yr/yr, beating analyst expectations

Adjusted EBITDA for Q3 beats estimates, driven by product sales growth

Company raises 2025 net sales growth and adjusted EBITDA expectations

Outlook

MiMedx expects 2025 net sales growth in the mid-to-high teens percentage vs 2024

Company anticipates 2025 adjusted EBITDA margin at least mid-20% range on full year basis

MiMedx sees long-term annual net sales growth in low double-digits percentage

Result Drivers

WOUND PRODUCT SALES - 40% increase in Wound product sales driven by CELERA and EMERGE

SURGICAL PRODUCT SALES - 26% increase in Surgical product sales, including growth in AMNIOFIX, AMNIOEFFECT, and HELIOGEN

GROSS MARGIN IMPROVEMENT - Year-over-year increase in gross margin driven by product mix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$113.72 mln
$94.14 mln (4 Analysts)
Q3 Net Income
$16.74 mln
Q3 Adjusted EBITDA
Beat
$34.95 mln
$19.35 mln (2 Analysts)
Q3 Gross Profit
$95 mln
Q3 Operating Income
$22.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for MiMedx Group Inc is $12.00, about 42.7% above its October 28 closing price of $6.88

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nGNX6lBL3n

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)